No increased risk of severe COVID-19 in asthma treated with biologics
EURASIAN JOURNAL OF PULMONOLOGY, cilt.24, sa.2, ss.85-94, 2022 (ESCI)
- Yayın Türü: Makale / Tam Makale
- Cilt numarası: 24 Sayı: 2
- Basım Tarihi: 2022
- Doi Numarası: 10.14744/ejp.2022.9821
- Dergi Adı: EURASIAN JOURNAL OF PULMONOLOGY
- Derginin Tarandığı İndeksler: Emerging Sources Citation Index (ESCI), TR DİZİN (ULAKBİM)
- Sayfa Sayıları: ss.85-94
- Anahtar Kelimeler: Asthma, biologic agents, COVID-19, dupilumab, mepolizumab, omalizumab, INFECTION, DISEASE, THERAPY, PATIENT, TMPRSS2, PEOPLE, ACE2
- Çanakkale Onsekiz Mart Üniversitesi Adresli: Evet
Özet
BACKGROUND AND AIM: Biologics can be used safely for patients with severe asthma during the coronavirus pandemic, but there is still a lack of information regarding their effects during SARS-CoV-2 infection. The aim of this study was to evaluate the impact of biologic therapies on the course of SARS-CoV-2 infection and to assess the outcome of COVID-19 for severe asthmatics in pandemic conditions.